Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply

Documenti analoghi

• Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
  di: Neil Chanchlani, et al.
  Pubblicazione: (2024)
• Editorial: Distinct Challenges of Paediatric From Adult‐Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children
  di: Alessandro Molinaro, et al.
  Pubblicazione: (2024)
• Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
  di: Carolin V. Schneider, et al.
  Pubblicazione: (2024)
• Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
  di: Remo Panaccione
  Pubblicazione: (2024)
• Editorial: Quantity is important! Authors' reply
  di: Marika Rudler, et al.
  Pubblicazione: (2024)